Interestingly, the immunostimulatory effect of retinoids was diminished in the absence of CD8+ T cells [95], suggesting that the addition of retinoids to a treatment regimen would only be beneficial if CD8+ T cells were already primed in the tumor microenvironment, which is likely the major role of intralesional IL2 in this combination therapy. This evidence concerns the gene IL2 and neoplasm.